Deep conversations with the world's leading experts on GLP-1 medications, obesity medicine, and the companies shaping this market. Hosted by Ashwin Sharma, founder of the GLP-1 Digest newsletter.
GLP-1 Digest Podcast
Claim This Podcastby Ash Sharma
5.0(1 reviews)
7 episodes
Updated Daily
Accepts GuestsHas SponsorsLocation 🇬🇧
Podcast Overview
Deep conversations with the world's leading experts on GLP-1 medications, obesity medicine, and the companies shaping this market. Hosted by Ashwin Sharma, founder of the GLP-1 Digest newsletter.
Language
🇺🇲
Publishing Since
2/13/2026
1 verified contact email on file for GLP-1 Digest Podcast
Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.
Recent Episodes
July 8, 2026
Can AI Stop GLP-1 Patients From Churning? Ep. 8 with Dr. Paul Sacher
<p>The economics of DTC GLP-1 care are getting harder. Customer acquisition costs keeps rising, price is getting pushed down, and more patients are willing to switch provider for the cheapest pen.</p><p>That leaves DTC companies with the worst possible equation: lower gross profit per month and a customer base full of switchers who may not stay long enough to pay back acquisition.</p><p>In this episode, I speak with Dr. Paul Sacher about where AI can actually show up on the GLP-1 profit and loss statement. Paul has spent more than two decades in obesity management and has worked across digital-health providers building and evaluating patient-facing AI systems. </p><p>His team has analysed close to 100,000 support tickets, churn data, and patient interviews, which makes this a practical conversation rather than another abstract debate about healthcare chatbots.</p><p><strong>Timestamps: </strong>00:00 Why AI in GLP-1 care is not just a chatbot</p><p>04:58 Why 24/7 support matters for patients</p><p>07:19 Onboarding, side effects, and early churn</p><p>12:18 Why app engagement can mislead operators</p><p>15:39 Switchers, maintenance, and personalised support</p><p>20:00 What providers get wrong when adding AI</p><p>37:46 The behavioural data moat in GLP-1 care</p><p>48:35 Safety, regulation, and clinical escalation</p><p><br></p><p>Subscribe to the newsletter: <a href="https://www.glp1digest.com/" target="_blank" rel="noopener noreferer">https://www.glp1digest.com/</a><br></p>
June 14, 2026
Genetics Could Decide Who Wins the GLP-1 Market, Ep. 7 with 23andMe’s Dr. Adam Auton
<p>Why do two people taking the same GLP-1 have radically different results? Part of the answer may be written in their DNA.Dr. Adam Auton is Vice President of Human Genetics at 23andMe and a senior author of the 2026 Nature study, <a href="https://www.nature.com/articles/s41586-026-10330-z" target="_blank" rel="ugc noopener noreferrer">“Genetic predictors of GLP1 receptor agonist weight loss and side effects.”</a> </p><p>The study examined 27,885 GLP-1 users to investigate whether genetic variation can help predict weight loss, nausea, and vomiting.</p><p>In this episode, we discuss what polygenic risk scores actually reveal, why genetics is risk rather than fate, and how variants in the GLP1R and GIPR genes may shape a patient’s response to semaglutide and tirzepatide.</p><p>We also explore the commercial consequences. As the obesity-drug market becomes more crowded, genetics could help new entrants identify patients who respond poorly to existing treatments, support more personalised care, and turn patient selection into a source of competitive advantage.</p><p>Read and subscribe to GLP-1 Digest: <a href="https://www.glp1digest.com/" target="_blank" rel="ugc noopener noreferrer">https://www.glp1digest.com/</a></p><p><br /></p><p>Timestamps: </p><p> 00:00 Polygenic risk scores and why genetics is not fate</p><p> 17:39 Why genetic risk scores vary by ancestry</p><p> 24:03 Inside 23andMe’s GLP-1 response study</p><p> 27:24 Predicting weight loss and side effects from DNA</p><p> 33:09 How reliable are self-reported data and prediction models?</p><p> 39:48 Genetics and the next generation of obesity drugs</p><p> 44:57 Can genetics predict weight regain after GLP-1s?</p><p> 48:11 Could genetics decide who wins the GLP-1 market?</p>
May 17, 2026
🎧 Can Peptides Become a Real DTC Business? Ep.6 with Tim Gutwald
<p>Peptides may already be a billion-dollar grey market. But if they move into legal compounding, can they become a real DTC healthcare business?</p><p><br></p><p>I speak with Tim Gutwald, a healthtech lawyer with roughly 20 years of experience across telehealth, prescribing, compounding and DTC healthcare, about the three things founders need to get right: legitimate pharma-grade API, defensible clinical protocols & enough internal data to market peptides beyond vague wellness claims.</p><p><br></p><p>We also discuss whether peptides are likely to become a standalone category, or simply a cross-sell around GLP-1s, TRT and longevity.</p><p><br></p><p>Subscribe: <a href="https://www.glp1digest.com/subscribe" target="_blank" rel="noopener noreferer">https://www.glp1digest.com/subscribe</a></p><p><br></p><p> <strong>Chapters</strong></p><p>00:00 What is happening in the peptide market?</p><p>03:01 Category 1, Category 2, and the FDA review process</p><p>08:19 Why DTC demand is driving regulation</p><p>10:41 Pharma-grade API and the peptide supply-chain problem</p><p>14:46 Clinicians, protocols, and prescribing risk</p><p>20:16 Advertising claims, testimonials, and internal data</p><p>30:00 What founders need to get right before launching</p><p>38:23 Schedule II drugs, telehealth prescribing, and affiliate risk</p><p>51:59 Why affiliate marketing is risky in DTC healthcare</p>
7 total episodes available
Similar Podcasts
Discover related shows you might enjoy
The GLP-1 Podcast Show
Wisenetix
Game-Changing Health
Gianna Beasley
The Plus SideZ: Cracking the Obesity Code
Kim Carlos
Drop The Weight with Elizabeth McGann
Elizabeth McGann
GLP-1 Hub: Support, Community, and Weight Loss
Ana Reisdorf, MS, RD
On The Pen GLP-1 News
Dave Knapp GLP-1 Industry Insider
The Life During And After GLP-1 Podcast
Daryl Perry
Everything GLP-1
NINETY EIGHT STUDIOS
Barbell Medicine Podcast
Barbell Medicine
Fat Science
Dr Emily Cooper
Docs Who Lift
Docs Who Lift
The Proof with Simon Hill
Live better for longer
The Hormone Solution with Karen Martel
Karen Martel: Certified Hormone Specialist
The Doctor's Farmacy with Mark Hyman, M.D.
Dr. Mark Hyman
Deep-dive analytics for GLP-1 Digest Podcast
Frequently asked questions
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
- What is GLP-1 Digest Podcast?
- How often does this podcast release new episodes?
This podcast updates daily.
- Where can I listen to this podcast?
This podcast is available on 4 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
- Does this podcast accept guests?
Yes, this podcast regularly features guests.
Legal Disclaimer
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.